Učitavanje...
First oncolytic virus approved for melanoma immunotherapy
On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX(GM-CSF)) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc....
Spremljeno u:
| Izdano u: | Oncoimmunology |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4760283/ https://ncbi.nlm.nih.gov/pubmed/26942095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1115641 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|